Croda International Plc (LON:CRDA - Get Free Report) insider Steve Foots purchased 5 shares of the business's stock in a transaction on Monday, March 10th. The stock was purchased at an average cost of GBX 3,203 ($41.24) per share, with a total value of £160.15 ($206.19).
Steve Foots also recently made the following trade(s):
- On Monday, February 10th, Steve Foots acquired 5 shares of Croda International stock. The shares were purchased at an average cost of GBX 3,094 ($39.84) per share, for a total transaction of £154.70 ($199.18).
- On Friday, January 10th, Steve Foots bought 5 shares of Croda International stock. The stock was purchased at an average price of GBX 3,272 ($42.13) per share, with a total value of £163.60 ($210.63).
Croda International Stock Performance
CRDA traded down GBX 84 ($1.08) during trading on Tuesday, reaching GBX 3,088 ($39.76). 64,458,609 shares of the company's stock were exchanged, compared to its average volume of 3,656,637. The company has a market capitalization of £4.32 billion, a P/E ratio of 26.54, a PEG ratio of 1.40 and a beta of 0.74. The company has a quick ratio of 2.25, a current ratio of 2.72 and a debt-to-equity ratio of 30.90. The business has a 50 day moving average price of GBX 3,247.20 and a 200 day moving average price of GBX 3,580.63. Croda International Plc has a fifty-two week low of GBX 3,025.90 ($38.96) and a fifty-two week high of GBX 5,124 ($65.97).
Croda International (LON:CRDA - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported GBX 142.60 ($1.84) earnings per share for the quarter. Croda International had a net margin of 9.98% and a return on equity of 6.96%. As a group, analysts predict that Croda International Plc will post 181.8307268 earnings per share for the current fiscal year.
Croda International Company Profile
(
Get Free Report)
Founded in 1925 with the aim of turning bio-based raw materials into innovative ingredients, Croda International is a speciality chemicals company focused on consumer care and life sciences markets. The company is focused on creating, making and selling innovative ingredients that deliver real benefits to a diverse range of customers and employs more than 6,000 people around the world.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Croda International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Croda International wasn't on the list.
While Croda International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
